Skip to content

Biomarkers, Smoking Topography, Nicotine Kinetics, and Subjective Smoking Experience with Flavored, Nicotine-Containing HTP Products Based on Rooibos by the Brand glo

Biomarkers, Smoking Topography, Nicotine Kinetics, and Subjective Smoking Experience with Flavored, Nicotine-Containing HTP Products Based on Rooibos by the Brand glo - Nicotide veo

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00034338
Enrollment
20
Registered
2024-06-17
Start date
2024-07-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco addiction F17.2

Interventions

Group 1: Intervention Group 1/4: glo veo Scarlet Click (without activated aroma capsule) All study participants undergo all four arms after an informational session. There is a washout period of at l

Sponsors

LMU Klinikum München - Klinik für Psychiatrie und Psychotherapie
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: a. Participant between 18 and 55 years old b. Lifetime smoker (=100 cigarettes in lifetime) c. Self-declaration as an occasional smoker (at least one cigarette within the last 30 days and at least one cigarette every 30 days, as well as smoking events on a maximum of 3 days per week) and smoker who inhales the smoke d. At least 24 hours of smoking abstinence before the start of testing e. Baseline nicotine plasma concentration < 10ng/ml f. Capacity to provide informed consent

Exclusion criteria

Exclusion criteria: a. Participant under 18 or over 55 years of age b. Non-smoker c. Tobacco dependence according to ICD-10 / FTND = 2 / PSCDI = 3 i. Daily cigarette consumption ii. Frequent regular consumption of other nicotine products d. Existing pregnancy i. For contraceptive methods with a Pearl Index > 0.9, a negative pregnancy test must be present before the start of testing e. Psychiatric pre-existing conditions i. Acute suicidality ii. Acute psychiatric disorders according to ICD-10 iii. Substance abuse, medication abuse, alcohol abuse at the time of the study f. Internal medicine pre-existing conditions i. Acute malignant cancer ii. Malignant cancers in the last 5 years iii. Severe pre-existing conditions / risk factors of the cardiovascular system 1. Manifest arterial hypertension 2. Severe cardiac pre-existing conditions (history of heart attack, heart failure) 3. Pacemaker 4. Diabetes mellitus iv. Respiratory diseases (such as asthma, COPD) v. Severe active infectious diseases (hepatitis, HIV) g. CO > 5ppm in exhaled breath h. Other circumstances that, in the opinion of the investigator, speak against participation in the study

Design outcomes

Primary

MeasureTime frame
Assessment of changes in smoking behavior, subjective smoking experience, and side effects including cardiovascular parameters when consuming novel tobacco products based on rooibos (glo veo Scarlet Click) compared to conventional tobacco cigarettes and tobacco sticks.

Secondary

MeasureTime frame
Assessment of nicotine kinetics in the acute phase, as well as changes in cytokine response and biomarkers when consuming novel tobacco products based on rooibos (glo veo Scarlet Click) compared to conventional tobacco cigarettes and tobacco sticks.

Countries

Germany

Contacts

Public ContactAndrea Rabenstein

LMU Klinikum München - Klinik für Psychiatrie und Psychotherapie

Andrea.Rabenstein@med.uni-muenchen.de+49 89440055539

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026